
PDMP Naloxone Co-Prescribing Fact Sheet





- Overdose is the leading cause of injury-related death in the United States, yet an opioid overdose can be preventable.
- Maryland regulations (COMAR 10.13.03) support the co-prescribing of naloxone for patients at elevated risk of experiencing or witnessing an overdose, as described below.
- **Naloxone** is an FDA-approved prescription medication that reverses opioid overdose by restoring breathing.
- Naloxone is commonly known by the brand name "Narcan".

WHAT STEPS CAN HEALTH CARE PROVIDERS TAKE?

- Health care providers regularly care for patients who are at risk of experiencing or witnessing an overdose and are therefore uniquely positioned to prevent future overdoses. Providers can deliver quality care to patients to prevent future overdose deaths in their communities by:
 - Routinely assessing risk of substance use disorder and overdose in patients who are prescribed short- and long-term opioids
 - Offering substance use disorder treatment or specialty pain management referrals, where appropriate
 - Continuing to engage patients in care regardless of active substance use or willingness to participate in substance use treatment
 - Educating patients about the risks of opioids, how to reduce risks and harm associated with use, and how to administer naloxone
 - Co-prescribing naloxone: Maryland law allows any health care provider with prescribing authority (including physicians, physician assistants, advance practice nurses, dentists, and podiatrists) to prescribe naloxone
 - Documenting patient interactions: licensed health care providers should document in their patients' medical records any education and clinical services provided that are related to opioid overdose risk reduction, such as prescribing naloxone, in accordance with the standard of care
 - Educating patients on how to obtain naloxone from a pharmacy if the patient knows someone who struggles with prescription or illicit opioids (e.g. Heroin)





PDMP Naloxone Co-Prescribing Fact Sheet

WHO IS AT RISK OF AN OVERDOSE?

- Individuals at risk of experiencing or witnessing an opioid overdose include, but are not limited, to:
 - Those who have been prescribed opioids for pain (including patients with long-term opioid use)
 - Those who have been treated for an opioid use disorder
 - Those who have received prescriptions for both an opioid and a benzodiazepine
 - Those who reside or spend time with an individual who is prescribed opioids, misuses opioids, or has an opioid use disorder
 - Those who resume opioid use after a period of ceasing or reducing opioid use (perceived tolerance may be different from actual tolerance)
 - Those who have respiratory problems such as chronic obstructive pulmonary disease (COPD) or sleep apnea

REMEMBER TO SCREEN PATIENT FOR OUD

SBIRT (Screening, Brief Intervention, and Referral to Treatment) is an evidence-based, comprehensive, and integrated public health approach to the delivery of early intervention and treatment services to patients who have risky alcohol or drug use.

Please visit https://bha.health.maryland.gov/Pages/SBIRT.aspx for more information.

Co-prescribing naloxone to individuals at elevated risk of having or witnessing an opioid overdose has been endorsed by the American Medical Association (AMA) and recommended by the Centers for Disease Control and Prevention (CDC).

Facts about Naloxone	Naloxone does NOT:
 Formulations available for intramuscular and	 Cause addiction "Enable" someone's drug use or addiction Give the user a "high" Increase risky drug use Have potential to cause harm when administered
intranasal delivery Safe for children and pregnant women Effects last 30-90 minutes Side effects are rare Can be safely administrated by laypersons Only effective in reversing overdoses involving opioids	appropriately, even if the person is not actually experiencing
and has no effect on someone who has not taken opioids No potential for misuse May lead to increased access to substance use treatment	an opioid overdose

MARYLAND STANDING ORDER

Patients may obtain naloxone from a pharmacy by presenting a prescription written by their health care provider. In the absence of such a prescription, individuals in Maryland can obtain naloxone from a pharmacy through the statewide standing order. Laura Herrera Scott, MD, MPH, Secretary, Maryland Department of Health, has issued a statewide standing order allowing all Maryland-licensed pharmacists to dispense naloxone, including the necessary supplies for administration, to anyone who may be at risk for opioid overdose or in a position to assist someone believed to be experiencing opioid overdose. A person-specific paper or electronic prescription is not required for a pharmacist to dispense naloxone under the standing order.

For more information visit: NaloxoneMD.org

